Journal of International Oncology ›› 2020, Vol. 47 ›› Issue (7): 385-390.doi: 10.3760/cma.j.cn371439-20200221-00042
• Orginal Article • Next Articles
Liu Jiaming, Yuan Shanshan, Wang Yu, Si Wangli()
Received:
2020-02-21
Revised:
2020-04-21
Online:
2020-07-08
Published:
2020-08-18
Contact:
Si Wangli
E-mail:onelisi@163.com
Liu Jiaming, Yuan Shanshan, Wang Yu, Si Wangli. Effects of silencing PRMT6 gene on proliferation and migration of gastric cancer cells[J]. Journal of International Oncology, 2020, 47(7): 385-390.
[1] |
Li T, Mo X, Fu L, et al. Molecular mechanisms of long noncoding RNAs on gastric cancer[J]. Oncotarget, 2016,7(8):8601-8612. DOI: 10.18632/oncotarget.6926.
doi: 10.18632/oncotarget.6926 pmid: 26788991 |
[2] |
Zong L, Abe M, Seto Y, et al. The challenge of screening for early gastric cancer in China[J]. Lancet, 2016,388(10060):2606. DOI: 10.1016/S0140-6736(16)32226-7.
doi: 10.1016/S0140-6736(16)32226-7 pmid: 27894662 |
[3] |
Veland N, Hardikar S, Zhong Y, et al. The arginine methyltransferase PRMT6 regulates DNA methylation and contributes to global DNA hypomethylation in cancer[J]. Cell Rep, 2017,21(12):3390-3397. DOI: 10.1016/j.celrep.2017.11.082.
doi: 10.1016/j.celrep.2017.11.082 pmid: 29262320 |
[4] |
Yoshimatsu M, Toyokawa G, Hayami S, et al. Dysregulation of PRMT1 and PRMT6, type Ⅰ arginine methyltransferases, is involved in various types of human cancers[J]. Int J Cancer, 2011,128(3):562-573. DOI: 10.1002/ijc.25366.
pmid: 20473859 |
[5] |
Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemi-ology, prevention, classification, and treatment[J]. Cancer Manag Res, 2018,10:239-248. DOI: 10.2147/CMAR.S149619.
doi: 10.2147/CMAR.S149619 pmid: 29445300 |
[6] | Chan LH, Zhou L, Ng KY, et al. PRMT6 regulates RAS/RAF binding and MEK/ERK-mediated cancer stemness activities in hepatocellular carcinoma through CRAF methylation[J]. Cell Rep, 2018, 25(3): 690-701. e8. DOI: 10.1016/j.celrep.2018.09.053. |
[7] |
Wang L, Zhao Z, Meyer MB, et al. CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis[J]. Cancer Cell, 2014,30(1):179-180. DOI: 10.1016/j.ccell.2016.06.013.
doi: 10.1016/j.ccell.2016.06.013 pmid: 27479032 |
[8] |
Almeida-Rios D, Graça I, Vieira FQ, et al. Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer[J]. Oncotarget, 2016,7(33):53018-53028. DOI: 10.18632/oncotarget.10061.
pmid: 27323813 |
[9] |
Okuno K, Akiyama Y, Shimada S, et al. Asymmetric dimethylation at histone H3 arginine 2 by PRMT6 in gastric cancer progression[J]. Carcinogenesis, 2019,40(1):15-26. DOI: 10.1093/carcin/bgy147.
doi: 10.1093/carcin/bgy147 pmid: 30508037 |
[10] |
Castro-Castro A, Marchesin V, Monteiro P, et al. Cellular and molecular mechanisms of MT1-MMP-dependent cancer cell invasion[J]. Annu Rev Cell Dev Biol, 2016,32:555-576. DOI: 10.1146/annurev-cellbio-111315-125227.
doi: 10.1146/annurev-cellbio-111315-125227 pmid: 27501444 |
[11] |
Conrad C, Götte M, Schlomann U, et al. ADAM8 expression in breast cancer derived brain metastases: functional implications on MMP-9 expression and transendothelial migration in breast cancer cells[J]. Int J Cancer, 2018,142(4):779-791. DOI: 10.1002/ijc.31090.
doi: 10.1002/ijc.31090 pmid: 28986926 |
[12] |
Shi M, Cao M, Song J, et al. PinX1 inhibits the invasion and metastasis of human breast cancer via suppressing NF-κB/MMP-9 signaling pathway[J]. Mol Cancer, 2015,14:66. DOI: 10.1186/s12943-015-0332-2.
doi: 10.1186/s12943-015-0332-2 pmid: 25888829 |
[13] |
Kong D, Li Y, Wang Z, et al. Inhibition of angiogenesis and invasion by 3, 3'-diindolylmethane is mediated by the nuclear factor-kappa B downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer[J]. Cancer Res, 2007,67(7):3310-3319. DOI: 10.1158/0008-5472.CAN-06-4277.
doi: 10.1158/0008-5472.CAN-06-4277 pmid: 17409440 |
[14] |
Song L, Liu L, Wu Z, et al. Knockdown of stomatin-like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF-κB/MMP-9 pathway[J]. J Pathol, 2012,226(3):534-543. DOI: 10.1002/path.3008.
pmid: 21960069 |
[15] |
Tsai KD, Lee WX, Chen W, et al. Upregulation of PRMT6 by LPS suppresses Klotho expression through interaction with NF-κB in glomerular mesangial cells[J]. J Cell Biochem, 2018,119(4):3404-3416. DOI: 10.1002/jcb.26511.
doi: 10.1002/jcb.26511 pmid: 29131380 |
[1] | Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[7] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[8] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[9] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[10] | Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[11] | Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[12] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[13] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[14] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281. |
[15] | Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||